A Key Regulator of Tumor Progression and Immunomodulation

Total Page:16

File Type:pdf, Size:1020Kb

A Key Regulator of Tumor Progression and Immunomodulation cancers Review Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation Hannah R. Moorman 1, Dakota Poschel 1,2,3, John D. Klement 1,2,3, Chunwan Lu 1,2,3, Priscilla S. Redd 4 and Kebin Liu 1,2,3,* 1 Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA; [email protected] (H.R.M.); [email protected] (D.P.); [email protected] (J.D.K.); [email protected] (C.L.) 2 Georgia Cancer Center, Medical College of Georgia, Augusta, GA 30912, USA 3 Charlie Norwood VA Medical Center, Augusta, GA 30904, USA 4 Chemedimmune Inc., Augusta, GA 30912, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-706-721-9483 Received: 22 October 2020; Accepted: 10 November 2020; Published: 15 November 2020 Simple Summary: Anti-PD-1/PD-L1 and anti-CTLA-4-based immune checkpoint blockade (ICB) immunotherapy have recently emerged as a breakthrough in human cancer treatment. Durable efficacy has been achieved in many types of human cancers. However, not all human cancers respond to current ICB immunotherapy and only a fraction of the responsive cancers exhibit efficacy. Osteopontin (OPN) expression is highly elevated in human cancers and functions as a tumor promoter. Emerging data suggest that OPN may also regulate immune cell function in the tumor microenvironment. This review aims at OPN function in human cancer progression and new findings of OPN as a new immune checkpoint. We propose that OPN compensates PD-L1 function to promote tumor immune evasion, which may underlie human cancer non-response to current ICB immunotherapy. Abstract: OPN is a multifunctional phosphoglycoprotein expressed in a wide range of cells, including osteoclasts, osteoblasts, neurons, epithelial cells, T, B, NK, NK T, myeloid, and innate lymphoid cells. OPN plays an important role in diverse biological processes and is implicated in multiple diseases such as cardiovascular, diabetes, kidney, proinflammatory, fibrosis, nephrolithiasis, wound healing, and cancer. In cancer patients, overexpressed OPN is often detected in the tumor microenvironment and elevated serum OPN level is correlated with poor prognosis. Initially identified in activated T cells and termed as early T cell activation gene, OPN links innate cells to adaptive cells in immune response to infection and cancer. Recent single cell RNA sequencing revealed that OPN is primarily expressed in tumor cells and tumor-infiltrating myeloid cells in human cancer patients. Emerging experimental data reveal a key role of OPN is tumor immune evasion through regulating macrophage polarization, recruitment, and inhibition of T cell activation in the tumor microenvironment. Therefore, in addition to its well-established direct tumor cell promotion function, OPN also acts as an immune checkpoint to negatively regulate T cell activation. The OPN protein level is highly elevated in peripheral blood of human cancer patients. OPN blockade immunotherapy with OPN neutralization monoclonal antibodies (mAbs) thus represents an attractive approach in human cancer immunotherapy. Keywords: osteopontin; CD44; integrin; tumor-associated macrophage; MDSCs; immune evasion; immune checkpoint 1. Introduction Osteopontin (OPN), a phosphorylated glycoprotein, was originally identified as a secreted form in bone and later discovered as an intracellular protein [1,2]. OPN is widely expressed in osteoclasts; Cancers 2020, 12, 3379; doi:10.3390/cancers12113379 www.mdpi.com/journal/cancers Cancers 2020, 12 2 of 31 1. Introduction Cancers 2020, 12, 3379 2 of 31 Osteopontin (OPN), a phosphorylated glycoprotein, was originally identified as a secreted form in bone and later discovered as an intracellular protein [1,2]. OPN is widely expressed in osteoclasts; osteoblasts;osteoblasts; epithelial epithelial cells cells of of th thee breast, breast, kidney, kidney, and and skin; skin; nerve nerve cells; cells; vascular vascular smooth smooth muscle muscle cells; cells;endothelial endothelial cells; cells;and andfibroblasts fibroblasts [3,4]. [3 ,A4]. broa A broadd range range of ofimmune immune cells cells such such as as macrophages,macrophages, lymphocytes,lymphocytes, natural killer cells,cells, eosinophils, de dendriticndritic cells, and microglia express OPN [5–11]. [5–11]. GivenGiven OPN’sOPN’s widewide expressionexpression profile,profile, itit followsfollows thatthat OPNOPN isis notnot onlyonly importantimportant forfor normalnormal biologicalbiological functioningfunctioning suchsuch as as bone bone remodeling, remodeling, immunity, immunity, and inflammation, and inflammation, but also playsbut also a role plays in pathological a role in processespathological such processes as liver fibrosis,such as liver atherosclerosis, fibrosis, atheroscle and cancerrosis, [12 and,13]. cancer [12,13]. InIn cancercancer patients,patients, OPNOPN isis oftenoften overexpressedoverexpressed inin cellscells ofof thethe tumortumor microenvironmentmicroenvironment andand elevatedelevated in the peripheral blood. blood. OPN OPN overexpressi overexpressionon has has been been associated associated with with worse worse prognosis prognosis in inmany many cancers cancers including including glioblastoma glioblastoma multiforme, multiforme, hepatocellular hepatocellular carcinoma, carcinoma, colorectal colorectal cancer, cancer, lung lungcancer, cancer, breast breast cancer, cancer, bladder bladder cancer, cancer, melanoma, melanoma, head headand neck and necksquamous squamous cell carcinoma, cell carcinoma, and acute and acutemyeloid myeloid leukemia leukemia [14–39]. [14 –OPN39]. OPNcontributes contributes to the to malignancy the malignancy of cancer of cancer through through the the promotion promotion of ofmetastasis, metastasis, maintenance maintenance of ofa astem-like stem-like phenotyp phenotype,e, epithelial epithelial to to mesenchymal transformation,transformation, activationactivation ofof cell proliferation pathways, chemotherapeutic andand radiation resistance, andand interference withwith immuneimmune functioning.functioning. As such,such, understanding OPN’sOPN’s regulationregulation andand mechanismsmechanisms ofof actionaction willwill provideprovide potentialpotential treatmenttreatment optionsoptions inin thethe future.future. In this review, we attempt to address the rolerole ofof OPNOPN inin cancerscancers includingincluding clinicalclinical data,data, mechanisms,mechanisms, regulation,regulation, andand potentialpotential treatmenttreatmentstrategies. strategies. 2.2. The OPN Protein OPNOPN isis aa membermember ofof thethe SIBLINGSIBLING (Small(Small Integrin-BindingIntegrin-Binding Ligand,Ligand, N-linkedN-linked Glycoprotein)Glycoprotein) familyfamily ofof proteinsproteins [[40].40]. OPN, also known as secreted phosphoprotein 1,1, isis encoded byby a single-copy gene,gene, spp1spp1, ,on on human human chromosome chromosome 4 near 4 near the centromere the centromere [41]. It [41 has]. several It has conserved several conserved structural structuraldomains including domains an including RGD domain an RGD (arginine-glycine-aspartate), domain (arginine-glycine-aspartate), SVVYGLR domain SVVYGLR (Serine-valine- domain (Serine-valine-valine-tyrosine-glutamate-leucine-arginine),valine-tyrosine-glutamate-leucine-arginine), heparin-binding heparin-binding domain, calcium-binding domain, calcium-binding domains, domains,cleavage sites cleavage for matrix sitesfor metalloproteinases, matrix metalloproteinases, and CD44 andreceptor-binding CD44 receptor-binding domain [42–49]. domain Five [42 OPN–49]. Fivesplice OPN variants splice have variants been identified. have been OPNa identified. (full-length OPNa (full-lengthisoform) contains isoform) all seven contains exons all sevenwhile OPNb exons whilelacks exon OPNb 5 lacksand OPNc exon 5lacks and exon OPNc 4 lacks(Figure exon 1). 4OPN4 (Figure lacks1). OPN4exons lacks4 and exons 5 and 4 OPN5 and 5 andcontains OPN5 all containsseven exons all seven plus exonsan extra plus exon an extra (yields exon alternativ (yields alternativee translation translation start) between start) between the third the and third fourth and fourthexons [50]. exons It [remains50]. It remains to be determined to be determined whether whether OPN4 and OPN4 OPN5 and transcripts OPN5 transcripts are translated are translated to protein. to protein.Unique Uniquephosphorylation phosphorylation sites and sites transglutaminase and transglutaminase cross-linking cross-linking sites allow sites allowfor structural for structural and andfunctional functional differences differences between between isoforms isoforms [48]. [ 48Differe]. Diffntialerential expression expression of OPN of OPN isoforms isoforms is likely is likely to tocontribute contribute to tocancer-specific cancer-specific progression. progression. For For example, example, OPNc OPNc supports supports anchorage anchorage independence independence and andinvasiveness invasiveness in breast in breast cancer cancer while OPNa while and OPNa OPNb and promote OPNb promotemigration migration in hepatocellular in hepatocellular carcinoma carcinoma[51–53]. [51–53]. FigureFigure 1.1. Human OPN protein structures.structures. The human SPP1 genes that encodes thethe OPNOPN proteinprotein hashas sevenseven exons.exons. Three alternativealternative splicedspliced OPNOPN variantsvariants translatetranslate toto protein.protein. TheThe receptor-interactingreceptor-interacting domainsdomains areare shown.shown. The respective receptorsreceptors forfor thesethese domainsdomains areare shownshown atat thethe bottom.bottom. Cancers
Recommended publications
  • Cellular Responses to Erbb-2 Overexpression in Human Mammary Luminal Epithelial Cells: Comparison of Mrna and Protein Expression
    British Journal of Cancer (2004) 90, 173 – 181 & 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $25.00 www.bjcancer.com Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression SL White1, S Gharbi1, MF Bertani1, H-L Chan1, MD Waterfield1 and JF Timms*,1 1 Ludwig Institute for Cancer Research, Wing 1.1, Cruciform Building, Gower Street, London WCIE 6BT, UK Microarray analysis offers a powerful tool for studying the mechanisms of cellular transformation, although the correlation between mRNA and protein expression is largely unknown. In this study, a microarray analysis was performed to compare transcription in response to overexpression of the ErbB-2 receptor tyrosine kinase in a model mammary luminal epithelial cell system, and in response to the ErbB-specific growth factor heregulin b1. We sought to validate mRNA changes by monitoring changes at the protein level using a parallel proteomics strategy, and report a surprisingly high correlation between transcription and translation for the subset of genes studied. We further characterised the identified targets and relate differential expression to changes in the biological properties of ErbB-2-overexpressing cells. We found differential regulation of several key cell cycle modulators, including cyclin D2, and downregulation of a large number of interferon-inducible genes, consistent with increased proliferation of the ErbB-2- overexpressing cells. Furthermore, differential expression of genes involved in extracellular matrix modelling and cellular adhesion was linked to altered adhesion of these cells. Finally, we provide evidence for enhanced autocrine activation of MAPK signalling and the AP-1 transcription complex.
    [Show full text]
  • Age- and Gender-Specific Modulation of Serum Osteopontin and Interferon-Α by Osteopontin Genotype in Systemic Lupus Er
    Genes and Immunity (2009) 10, 487–494 & 2009 Macmillan Publishers Limited All rights reserved 1466-4879/09 $32.00 www.nature.com/gene ORIGINAL ARTICLE Age- and gender-specific modulation of serum osteopontin and interferon-a by osteopontin genotype in systemic lupus erythematosus SN Kariuki1, JG Moore1, KA Kirou2,MKCrow2, TO Utset1 and TB Niewold1 1Section of Rheumatology, University of Chicago, Chicago, IL, USA and 2Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, USA Osteopontin (OPN) is a multifunctional cytokine involved in long bone remodeling and immune system signaling. Additionally, OPN is critical for interferon-a (IFN-a) production in murine plasmacytoid dendritic cells. We have previously shown that IFN-a is a heritable risk factor for systemic lupus erythematosus (SLE). Genetic variants of OPN have been associated with SLE susceptibility, and one study suggests that this association is particular to men. In this study, the 3 0 UTR SLE-risk variant of OPN (rs9138C) was associated with higher serum OPN and IFN-a in men (P ¼ 0.0062 and P ¼ 0.0087, respectively). In women, the association between rs9138 C and higher serum OPN and IFN-a was restricted to younger subjects, and risk allele carriers showed a strong age-related genetic effect of rs9138 genotype on both serum OPN and IFN-a (Po0.0001). In African- American subjects, the 5 0 region single nucleotide polymorphisms, rs11730582 and rs28357094, were associated with anti- RNP antibodies (odds ratio (OR) ¼ 2.9, P ¼ 0.0038 and OR ¼ 3.9, P ¼ 0.021, respectively). Thus, we demonstrate two distinct genetic influences of OPN on serum protein traits in SLE patients, which correspond to previously reported SLE-risk variants.
    [Show full text]
  • S100 Calcium-Binding Protein S100 Proteins
    S S100 Calcium-Binding Protein experiments showed the S100 protein fraction consti- tuted two different dimeric species comprised of two ▶ S100 Proteins b protomers (S100B) or an a, b heterodimer (Isobe et al. 1977). Early members of the S100 protein family were frequently given suffixes based on their localiza- tion or molecular size and included S100P (placental), S100 Proteins S100C (cardiac or calgizzarin), p11 (11 kDa), and MRP8/MRP14 (myeloid regulatory proteins, 8 and Brian R. Dempsey, Anne C. Rintala-Dempsey and 14 kDa). In 1993, initial genetic studies showed that Gary S. Shaw six of the S100 genes were clustered on chromosome Department of Biochemistry, The University of 1q21 (Engelkamp et al. 1993), a number that has Western Ontario, London, ON, Canada expanded since. Based on this observation most of the proteins were renamed according to the physical order they occupy on the chromosome. These include Synonyms S100A1 (formerly S100a), S100A2 (formerly S100L), S100A10 (p11), S100A8/S100A14 (MRP8/MRP14). S100 calcium-binding protein A few S100 proteins are found on other chromosomes including S100B (21q21). Currently there are 27 known S100 family members: S100A1-A18, S100B, S100 Protein Family Members S100G, S100P, S100Z, trichohylin, filaggrin, filaggrin- 2, cornulin, and repetin (Table 1). S100A1, S100A2, S100A3, S100A4, S100A5, S100A6, S100A7, S100A8, S100A9, S100A10, S100A11, S100A12, S100A13, S100A14, S100A15, S100A16, Role of S100 Proteins in Calcium Signaling S100B, S100P, S100G, S100Z, trichohylin, filaggrin, filaggrin-2,
    [Show full text]
  • S100P Interacts with P53 While Pentamidine Inhibits This Interaction
    biomolecules Article S100P Interacts with p53 while Pentamidine Inhibits This Interaction Revansiddha H. Katte 1 , Deepu Dowarha 1 , Ruey-Hwang Chou 2,3 and Chin Yu 1,* 1 Department of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan; [email protected] (R.H.K.); [email protected] (D.D.) 2 Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 40402, Taiwan; [email protected] 3 Department of Biotechnology, Asia University, Taichung 41354, Taiwan * Correspondence: [email protected]; Tel.: +886-963-780-784; Fax: +886-35-711082 Abstract: S100P, a small calcium-binding protein, associates with the p53 protein with micromolar affinity. It has been hypothesized that the oncogenic function of S100P may involve binding-induced inactivation of p53. We used 1H-15N HSQC experiments and molecular modeling to study the molecular interactions between S100P and p53 in the presence and absence of pentamidine. Our experimental analysis indicates that the S100P-53 complex formation is successfully disrupted by pentamidine, since S100P shares the same binding site for p53 and pentamidine. In addition, we showed that pentamidine treatment of ZR-75-1 breast cancer cells resulted in reduced proliferation and increased p53 and p21 protein levels, indicating that pentamidine is an effective antagonist that interferes with the S100P-p53 interaction, leading to re-activation of the p53-21 pathway and inhibition of cancer cell proliferation. Collectively, our findings suggest that blocking the association between S100P and p53 by pentamidine will prevent cancer progression and, therefore, provide a new avenue for cancer therapy by targeting the S100P-p53 interaction.
    [Show full text]
  • Differential Gene Expression in Colon Cancer of the Caecum Versus
    374 COLON CANCER Gut: first published as 10.1136/gut.2003.036848 on 11 February 2005. Downloaded from Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid K Birkenkamp-Demtroder, S H Olesen, F B Sørensen, S Laurberg, P Laiho, L A Aaltonen, T F Ørntoft ............................................................................................................................... Gut 2005;54:374–384. doi: 10.1136/gut.2003.036848 Background and aims: There are epidemiological, morphological, and molecular differences between normal mucosa as well as between adenocarcinomas of the right and left side of the large bowel. The aim of this study was to investigate differences in gene expression. Methods: Oligonucleotide microarrays (GeneChip) were used to compare gene expression in 45 single See end of article for samples from normal mucosa and sporadic colorectal carcinomas (Dukes’ B and C) of the caecum authors’ affiliations compared with the sigmoid and rectosigmoid. Findings were validated by real time polymerase chain ....................... reaction. Correspondence to: Results: Fifty eight genes were found to be differentially expressed between the normal mucosa of the Professor T F Ørntoft, caecum and the sigmoid and rectosigmoid (p,0.01), including pS2, S100P, and a sialyltransferase, all Molecular Diagnostic being expressed at higher levels in the caecum. A total of 118 and 186 genes were differentially expressed Laboratory, Department of Clinical Biochemistry, between normal and right or left sided tumours of the colon, showing more pronounced differences in Aarhus University Dukes’ C than B tumours. Thirty genes differentially expressed in tumour tissue were common to Hospital/Skejby, adenocarcinomas of both sides, including known tumour markers such as the matrix metalloproteinases.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Intracellular Cleavage of Osteopontin by Caspase-8 Modulates Hypoxia/Reoxygenation Cell Death Through P53
    Intracellular cleavage of osteopontin by caspase-8 modulates hypoxia/reoxygenation cell death through p53 Hyo-Jin Kima, Ho-June Leea, Joon-Il Junb, Yumin Oha, Seon-Guk Choia, Hyunjoo Kima, Chul-Woong Chungc, In-Ki Kimd, Il-Sun Parke, Han-Jung Chaef, Hyung-Ryong Kimg, and Yong-Keun Junga,1 aCreative Research Initiative Acceleration Research, School of Biological Science/Bio-Max Institute, Seoul National University, Seoul 151–747, Korea; bDepartment of Life Science, Gwangju Institute of Science and Technology, Gwangju 500–712, Korea; cLG Life Science Research Park, Daejon 305–389, Korea; dOntario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; eDepartment of Bio-Materials Engineering and Molecular Medicine, School of Medicine, Chosun University, Gwangju 501–759, Korea; fSchool of Medicine, Chonbuk National University, Chonbuk 560–180, Korea, and gDepartment of Dental Pharmacology, School of Dentistry, Wonkwang University, Chonbuk 570–749, Korea Edited by Harvey Cantor, Dana-Farber Cancer Institute, Boston, MA, and approved July 20, 2009 (received for review April 3, 2009) Osteopontin (OPN) is highly expressed in cancer patients and plays after massive generation of reactive oxygen species (ROS) and important roles in many stages of tumor progression, such as anti- caspases activation. Several caspases including caspases-8, -9, and -3 apoptosis, proliferation, and metastasis. From functional screening of were reported to be activated during reoxygenation, which is human cDNA library, we isolated OPN as a caspase-8 substrate that required for Hyp/RO-induced cell death (11, 12). Among these regulates cell death during hypoxia/reoxygenation (Hyp/RO). In vitro caspases, caspase-8 is a well known receptor-proximal caspase.
    [Show full text]
  • 1356 S100 Proteins: Structure, Functions And
    [Frontiers in Bioscience 7, d1356-1368, May 1, 2002] S100 PROTEINS: STRUCTURE, FUNCTIONS AND PATHOLOGY Claus W. Heizmann, Günter Fritz and Beat W. Schäfer Department of Pediatrics, Division of Clinical Chemistry and Biochemistry, University of Zürich, Steinwiesstrasse 75, CH- 8032 Zürich, Switzerland TABLE OF CONTENTS 1. Abstract 2. Introduction 3. The family of S100 proteins 3.1. Protein structures and target interactions 3.2. Genomic organization 3.3. Biological functions 3.4. Animal models 4. Associations with human diseases and diagnostics 5. Conclusion and perspectives 6. Acknowledgments 7. References 1. ABSTRACT S100 proteins regulate intracellular processes expression of some S100 genes associated with neoplasias. such as cell growth and motility, cell cycle regulation, Recently, S100 proteins have received increasing attention transcription and differentiation. Twenty members have due to their close association with several human diseases been identified so far, and altogether, S100 proteins including cardiomyopathy, neurodegenerative disorders represent the largest subgroup in the EF-hand Ca2+ -binding and cancer. They have also been proven to be valuable in protein family. A unique feature of these proteins is that the diagnostic of these diseases, as predictive markers of individual members are localized in specific cellular improving clinical management, outcome and survival of compartments from which some are able to relocate upon patients and are considered having a potential as drug Ca2+ activation, transducing the Ca2+ signal in a temporal targets to improve therapies. and spacial manner by interacting with different targets specific for each S100 protein. Some members are even 2. INTRODUCTION secreted from cells exerting extracellular, cytokine-like Calcium (Ca2+) functions as a messenger activities partially via the surface receptor RAGE (receptor regulating a great variety of cellular processes in a spatial for advanced glycation endproducts) with paracrine effects and temporal manner (1).
    [Show full text]
  • Gibco Expi293 Flier
    10x greater protein yield Expi293 Expression System In all my years working with transient expression systems, the Expi293™ Expression System is the fi rst one to achieve 2.3g/L, beating every other HEK 293 transient expression system. —Jelte-Jan Reitsma, Research Associate The Expi293 Expression System features: •“ Higher transfection effi ciency. • Improved cell viability. • Up to 10x greater protein yield. • Smaller culture volumes. ” The Gibco™ Expi293™ Expression System is a major advancement in transient expression technology for rapid and ultrahigh-yield protein production in mammalian cells. It is based on the high-density culture of Expi293F™ Cells in the Expi293™ Expression Medium. Transient expression is powered by the cationic, lipid-based ExpiFectamine™ 293 transfection reagent in combination with optimized transfection enhancers. All these components work in concert to generate 2- to 10-fold higher protein yields than conventional culture systems such as the Invitrogen™ FreeStyle™ 293 Expression System. Expression levels of greater than 1g/L were achieved for IgG and non-IgG proteins (Figure 1). Human lgG Cripto 1,200 1,200 1,000 1,000 800 800 600 600 400 400 hIgG (µg/mL) Cripto (µg/mL) 200 200 0 0 30mL culture 30mL culture FreeStyle 293 Expi293 Figure 1. Expression of Fc-tagged Cripto protein achieves expression levels of over 1g/L in the Expi293 Expression System. Yields of various proteins using the Expi293 Expression System Expi293 Expi293 Accession Accession Definition Gene yield Definition Gene yield number number (mg/L) (mg/L) Pleckstrin, mRNA (cDNA clone Tumor suppressor candidate 4, MGC:17111 IMAGE:4341823), complete PLEK A AH18549.1 5,610 mRNA (cDNA clone MGC:22898 NPRL2 AAH21984.1 175 cds IMAGE:4068981), complete cds Signal transducer and activator of N-myc downstream regulated 1 (NDRG1), NDRG1 NP_ 0 0 6 0 87.2 162 transcription 3 (acute-phase response STAT3 NP_644805.1 2,139 transcript variant 2, mRNA factor) (STAT3), transcript variant 1, mRNA MutS homolog 2, colon cancer, BH3 interacting domain death agonist nonpolyposis type 1 (E.
    [Show full text]
  • Gene Expression Signatures and Biomarkers of Noninvasive And
    Oncogene (2006) 25, 2328–2338 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc ORIGINAL ARTICLE Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics GM Nagaraja1, M Othman2, BP Fox1, R Alsaber1, CM Pellegrino3, Y Zeng2, R Khanna2, P Tamburini3, A Swaroop2 and RP Kandpal1 1Department of Biological Sciences, Fordham University, Bronx, NY, USA; 2Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA and 3Bayer Corporation, West Haven, CT, USA We have characterized comprehensive transcript and Keywords: representational difference analysis; micro- proteomic profiles of cell lines corresponding to normal arrays; proteomics; breast carcinoma; biomarkers; breast (MCF10A), noninvasive breast cancer (MCF7) and copper homeostasis invasive breast cancer (MDA-MB-231). The transcript profiles were first analysed by a modified protocol for representational difference analysis (RDA) of cDNAs between MCF7 and MDA-MB-231 cells. The majority of genes identified by RDA showed nearly complete con- Introduction cordance withmicroarray results, and also led to the identification of some differentially expressed genes such The transformation of a normal cell into a cancer cell as lysyl oxidase, copper transporter ATP7A, EphB6, has been correlated to altered expression of a variety of RUNX2 and a variant of RUNX2. The altered transcripts genes (Perou et al., 2000; Becker et al., 2005). The identified by microarray analysis were involved in cell–cell expression of some of these genes is a direct result of or cell–matrix interaction, Rho signaling, calcium home- sequence mutation, whereas other changes occur due to ostasis and copper-binding/sensitive activities.
    [Show full text]
  • Protein Expression Profiles in Pancreatic Adenocarcinoma
    [CANCER RESEARCH 64, 9018–9026, December 15, 2004] Protein Expression Profiles in Pancreatic Adenocarcinoma Compared with Normal Pancreatic Tissue and Tissue Affected by Pancreatitis as Detected by Two- Dimensional Gel Electrophoresis and Mass Spectrometry Jianjun Shen,1 Maria D. Person,2 Jijiang Zhu,3 James L. Abbruzzese,3 and Donghui Li3 1Department of Carcinogenesis, Science Park-Research Division, The University of Texas M. D. Anderson Cancer Center, Smithville, Texas; 2Division of Pharmacology and Toxicology, The University of Texas, Austin, Texas; and 3Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas ABSTRACT revealed a large number of differentially expressed genes but little overlap of identified genes among various gene expression ap- Pancreatic cancer is a rapidly fatal disease, and there is an urgent need proaches. Furthermore, although genetic mutation and/or errant gene for early detection markers and novel therapeutic targets. The current expression may underlie a disease, the biochemical bases for most study has used a proteomic approach of two-dimensional (2D) gel elec- trophoresis and mass spectrometry (MS) to identify differentially ex- diseases are caused by protein defects. Therefore, profiling differen- pressed proteins in six cases of pancreatic adenocarcinoma, two normal tially expressed proteins is perhaps the most important and useful adjacent tissues, seven cases of pancreatitis, and six normal pancreatic approach in development of diagnostic screening and therapeutic tissues. Protein extracts of individual sample and pooled samples of each techniques. type of tissues were separated on 2D gels using two different pH ranges. The proteomic approach has offered many opportunities and chal- Differentially expressed protein spots were in-gel digested and identified lenges in identifying new tumor markers and therapeutic targets and in by MS.
    [Show full text]
  • 1208.Full-Text.Pdf
    Published OnlineFirst June 19, 2019; DOI: 10.1158/2159-8290.CD-18-1454 RESEARCH ARTICLE Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Effi cacy in Triple-Negative Breast Cancer Jaclyn Sceneay 1 , 2 , Gregory J. Goreczny 1 , 2 , Kristin Wilson 1 , Sara Morrow 1 , Molly J. DeCristo 1 , 2 , Jessalyn M. Ubellacker1 , 2 , Yuanbo Qin 1 , 2 , Tyler Laszewski 1 , Daniel G. Stover 3 , Victor Barrera 4 , John N. Hutchinson 4 , Rachel A. Freedman 5 , 6 , Elizabeth A. Mittendorf 6 , 7 , and Sandra S. McAllister 1 , 2 , 8 , 9 ABSTRACT Immune checkpoint blockade (ICB) therapy, which targets T cell–inhibitory recep- tors, has revolutionized cancer treatment. Among the breast cancer subtypes, evaluation of ICB has been of greatest interest in triple-negative breast cancer (TNBC) due to its immunogenicity, as evidenced by the presence of tumor-infi ltrating lymphocytes and elevated PD-L1 expression relative to other subtypes. TNBC incidence is equally distributed across the age spectrum, affecting 10% to 15% of women in all age groups. Here we report that increased immune dysfunction with age limits ICB effi cacy in aged TNBC-bearing mice. The tumor microenvironment in both aged mice and patients with TNBC shows decreased IFN signaling and antigen presentation, suggesting failed innate immune activation with age. Triggering innate immune priming with a STING agonist restored response to ICB in aged mice. Our data implicate age-related immune dysfunction as a mechanism of ICB resistance in mice and suggest potential prognostic utility of assessing IFN-related genes in patients with TNBC receiving ICB therapy.
    [Show full text]